Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
weizmannia coagulans BC99
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Weizmannia coagulans BC99 (formerly known as Bacillus coagulans BC99) is a Gram-positive, spore-forming, lactic acid-producing probiotic strain developed and supplied by Wecare Probiotics. Originally isolated from the fecal sample of a healthy infant, it has received 'Generally Recognized as Safe' (GRAS) certification from the U.S. FDA. As a live biotherapeutic modality, BC99 acts by modulating the gut microbiota and influencing various systemic pathways, including inflammatory responses (Nrf2/NLRP3), neurotransmitter systems (5-HT, BDNF, MTL, AChE), and metabolic lipid pathways. It has been clinically investigated for its potential benefits in managing body weight and lipid profiles in overweight and obese individuals, as well as for conditions such as constipation, hyperuricemia, allergic rhinitis, and cognitive performance under sleep deprivation. It is primarily utilized as a dietary supplement and health product ingredient rather than an approved pharmaceutical drug.
- Brand names
- BC99BC-99BC 99
- Other names
- Bacillus coagulans BC99W. coagulans BC99B. coagulans BC99
Beyond the preview
Go deeper on weizmannia coagulans BC99.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on weizmannia coagulans BC99.